<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00858013</url>
  </required_header>
  <id_info>
    <org_study_id>AJIRB-CRO-08-197</org_study_id>
    <nct_id>NCT00858013</nct_id>
  </id_info>
  <brief_title>Study of the Durability of Glycemic Control With Nateglinide</brief_title>
  <official_title>Multi-center, Randomized, Open Label Study of the Durability of Glycemic Control With Nateglinide Versus Glimepiride as Monotherapy in Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hanyang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inha University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Myongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bundang CHA Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wonju Severance Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ajou University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-center, randomized controlled study aims to evaluate the durability and efficacy
      of nateglinide therapy for long term glycemic control compared with glimepiride.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Selected patients will be randomly assigned to receive nateglinide or glimepiride.

      Previous treatment with oral antidiabetic drugs (metformin, a-glucosidase inhibitor,
      nateglinide or sulfonylurea) will be discontinued. After a 1 month wash-out period (if 6.5 ≤
      HbA1c ≤ 8.5), patients will take randomly assigned drugs for 24 months.

      Patients will be met by the trial investigator every 3 months following randomization. At
      each visit, patients whose HbA1c is &gt; 8.0% will be retested 2 weeks later, and if the
      retested HbA1c is also above 8.0%, those patients will be withdrawn considering monotherapy
      failure. We will evaluate the durability of nateglinide in comparison with that of
      glimepiride based on the withdrawal rate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 24, 2009</start_date>
  <completion_date type="Actual">June 25, 2014</completion_date>
  <primary_completion_date type="Actual">June 25, 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Durability of Nateglinide in Comparison With Those of Glimepiride Based on the Withdrawal Rate</measure>
    <time_frame>every 3 months following randomization, for 24 months</time_frame>
    <description>% monotherapy failure, that means % number of participants who withdrew from the study due to high HbA1c (&gt;8.0%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>at 24 months</time_frame>
    <description>HbA1c (%) at 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Glucose</measure>
    <time_frame>at 24 months</time_frame>
    <description>fasting glucose (mg/dL) at 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide</measure>
    <time_frame>at 24 months</time_frame>
    <description>c-peptide(uU/mL) at 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA-IR</measure>
    <time_frame>at 24 months</time_frame>
    <description>insulin resistance marker HOMA-IR at 24 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Nateglinide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nateglinide 90~120mg three times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glimepiride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glimepiride 1~2mg once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nateglinide</intervention_name>
    <description>Nateglinide 90~120mg three times a day</description>
    <arm_group_label>Nateglinide</arm_group_label>
    <other_name>fastic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <description>Glimepiride 1~2mg once a day</description>
    <arm_group_label>Glimepiride</arm_group_label>
    <other_name>amaryl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetes mellitus

          -  age&gt;=18years

          -  no anti hyperglycemic agent for 3 months or low-dose oral hypoglycemic therapy

               -  metformin≤1g/day, acarbose≤300mg/day, voglibose≤0.9mg/day, nateglinide≤270mg/day,
                  gliclazide≤80mg/day, glimepiride≤2mg/day, glibenclamide≤5mg/day (nateglinide or
                  sulfonylurea &lt;6months)

          -  6.5% ≤ HbA1c ≤ 8.5%

               -  patients on no anti hyperglycemic agent for 3 months : HbA1c at screening

               -  patients on oral hypoglycemic therapy in 3months : HbA1c after wash-out

        Exclusion Criteria:

          -  attending other clinical trials in 3months

          -  type I diabetes mellitus

          -  taking systemic steroid in 1month or requiring steroid therapy during clinical trial

          -  acute myocardial infarction in 6months

          -  alcoholics, pituitary or adrenal insufficiency, severe ketosis, diabetic ketoacidosis

          -  severe liver disease or AST, ALT ≥ 2.5 x ULN

          -  renal insufficiency (serum creatinine &gt; 2.0mg/dl)

          -  other severe diabetic complication

          -  drug hypersensitivity history to nateglinide or sulfonylurea

          -  pregnant or plan to become pregnant during the clinical trial, lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kwan Woo Lee, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ajou University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Myongji Hospital</name>
      <address>
        <city>Ilsan</city>
        <state>Kyounggi</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyang University Medical Center</name>
      <address>
        <city>Guri-si</city>
        <state>Kyunggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyung hee University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2009</study_first_submitted>
  <study_first_submitted_qc>March 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2009</study_first_posted>
  <results_first_submitted>February 14, 2017</results_first_submitted>
  <results_first_submitted_qc>February 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 31, 2017</results_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ajou University School of Medicine</investigator_affiliation>
    <investigator_full_name>Kwan Woo Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Nateglinide</keyword>
  <keyword>Pancreatic beta cell function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Nateglinide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nateglinide</title>
          <description>Nateglinide 90~120mg three times a day
Nateglinide: Nateglinide 90~120mg three times a day</description>
        </group>
        <group group_id="P2">
          <title>Glimepiride</title>
          <description>Glimepiride 1~2mg once a day
Glimepiride: Glimepiride 1~2mg once a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nateglinide</title>
          <description>Nateglinide 90~120mg three times a day
Nateglinide: Nateglinide 90~120mg three times a day</description>
        </group>
        <group group_id="B2">
          <title>Glimepiride</title>
          <description>Glimepiride 1~2mg once a day
Glimepiride: Glimepiride 1~2mg once a day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="88"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.0" spread="10.5"/>
                    <measurement group_id="B2" value="55.1" spread="12.3"/>
                    <measurement group_id="B3" value="55" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Durability of Nateglinide in Comparison With Those of Glimepiride Based on the Withdrawal Rate</title>
        <description>% monotherapy failure, that means % number of participants who withdrew from the study due to high HbA1c (&gt;8.0%)</description>
        <time_frame>every 3 months following randomization, for 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nateglinide</title>
            <description>Nateglinide 90~120mg three times a day
Nateglinide: Nateglinide 90~120mg three times a day</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Glimepiride 1~2mg once a day
Glimepiride: Glimepiride 1~2mg once a day</description>
          </group>
        </group_list>
        <measure>
          <title>The Durability of Nateglinide in Comparison With Those of Glimepiride Based on the Withdrawal Rate</title>
          <description>% monotherapy failure, that means % number of participants who withdrew from the study due to high HbA1c (&gt;8.0%)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c</title>
        <description>HbA1c (%) at 24 months</description>
        <time_frame>at 24 months</time_frame>
        <population>data of participants who finished 24 months of follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Nateglinide</title>
            <description>Nateglinide 90~120mg three times a day
Nateglinide: Nateglinide 90~120mg three times a day</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Glimepiride 1~2mg once a day
Glimepiride: Glimepiride 1~2mg once a day</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c</title>
          <description>HbA1c (%) at 24 months</description>
          <population>data of participants who finished 24 months of follow-up</population>
          <units>% HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="0.6"/>
                    <measurement group_id="O2" value="6.5" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Glucose</title>
        <description>fasting glucose (mg/dL) at 24 months</description>
        <time_frame>at 24 months</time_frame>
        <population>data of participants who finished 24 months of follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Nateglinide</title>
            <description>Nateglinide 90~120mg three times a day
Nateglinide: Nateglinide 90~120mg three times a day</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Glimepiride 1~2mg once a day
Glimepiride: Glimepiride 1~2mg once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Glucose</title>
          <description>fasting glucose (mg/dL) at 24 months</description>
          <population>data of participants who finished 24 months of follow-up</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.2" spread="25.9"/>
                    <measurement group_id="O2" value="115.7" spread="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C-peptide</title>
        <description>c-peptide(uU/mL) at 24 months</description>
        <time_frame>at 24 months</time_frame>
        <population>data of participants who finished 24 months of follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Nateglinide</title>
            <description>Nateglinide 90~120mg three times a day
Nateglinide: Nateglinide 90~120mg three times a day</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Glimepiride 1~2mg once a day
Glimepiride: Glimepiride 1~2mg once a day</description>
          </group>
        </group_list>
        <measure>
          <title>C-peptide</title>
          <description>c-peptide(uU/mL) at 24 months</description>
          <population>data of participants who finished 24 months of follow-up</population>
          <units>uU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" spread="0.41"/>
                    <measurement group_id="O2" value="1.77" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HOMA-IR</title>
        <description>insulin resistance marker HOMA-IR at 24 months</description>
        <time_frame>at 24 months</time_frame>
        <population>data of participants who finished 24 months of follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Nateglinide</title>
            <description>Nateglinide 90~120mg three times a day
Nateglinide: Nateglinide 90~120mg three times a day</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Glimepiride 1~2mg once a day
Glimepiride: Glimepiride 1~2mg once a day</description>
          </group>
        </group_list>
        <measure>
          <title>HOMA-IR</title>
          <description>insulin resistance marker HOMA-IR at 24 months</description>
          <population>data of participants who finished 24 months of follow-up</population>
          <units>mg/dL x mIU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.40" spread="1.36"/>
                    <measurement group_id="O2" value="2.31" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nateglinide</title>
          <description>Nateglinide 90~120mg three times a day
Nateglinide: Nateglinide 90~120mg three times a day</description>
        </group>
        <group group_id="E2">
          <title>Glimepiride</title>
          <description>Glimepiride 1~2mg once a day
Glimepiride: Glimepiride 1~2mg once a day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>gall stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kwan Woo Lee</name_or_title>
      <organization>Ajou University</organization>
      <phone>82-31-219-4526</phone>
      <email>lkw65@ajou.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

